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Abstract
Aims: The SYNTAX score is a tool to quantify the complexity of coronary artery disease. We investi-
gated the relation between the SYNTAX score and the occurrence of a periprocedural myocardial infarc-
tion (PMI) according to the historical definition of the World Health Organization (WHO) and the recently 
updated universal definition of MI.
Methods and results: The SYNTAX score was calculated in 1,243 patients enrolled in TWENTE, a ran-
domised trial which assessed second-generation drug-eluting stents. PMI was defined by the WHO defi-
nition and the third universal definition of MI. Patients were divided into tertiles of the SYNTAX score: 
≤7 (n=430); >7 and <15 (n=390); ≥15 (n=423). PMI according to the WHO definition occurred more fre-
quently in patients in the highest SYNTAX score tertile (7.3% vs. 3.1% vs. 1.6%, p<0.001) compared to 
the mid and lowest tertile. Similar findings were seen for universal PMI (9.9% vs. 7.7% vs. 3.7%, p<0.01). 
After multivariate analysis, SYNTAX score was a significant independent correlate of PMI for both defi-
nitions: the highest SYNTAX score tertile had an almost five times higher risk for WHO PMI, and a three 
times higher risk for universal PMI.
Conclusions: In a broad patient population treated with second-generation DES, the SYNTAX score was 
able to stratify the risk of PMI.
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Abbreviations
CABG coronary artery bypass grafting
CK  creatine kinase
CK-MB creatine kinase-MB
DES drug-eluting stents
MI myocardial infarction
PCI percutaneous coronary intervention
PMI periprocedural myocardial infarction
STEMI ST-elevation myocardial infarction
WHO World Health Organization 
Introduction
The SYNTAX score is a tool for the assessment of the degree and 
complexity of atherosclerotic disease burden of coronary arter-
ies. It incorporates several pre-existing scoring systems such as 
the Leaman classification, American Heart Association/American 
College of Cardiology, modified BARI classification, and chronic 
total occlusion and bifurcation scores1.
Currently, the SYNTAX score is used mainly as a tool to evalu-
ate the suitability of patients with multivessel disease to undergo 
coronary artery bypass grafting (CABG) or percutaneous coronary 
intervention (PCI)2. In addition to this application, the SYNTAX 
score may also be useful to stratify the risk of periprocedural com-
plications. Myocardial infarction after a percutaneous coronary 
intervention (PCI) is the most common procedural complication 
and is an important endpoint in coronary stent trials3. There is 
controversy about the clinical impact of periprocedural myocar-
dial infarction (PMI); however, several studies have shown a rela-
tion between PMI and increased mortality4-6. So far, there are no 
established risk models for the prediction of PMI.
Therefore, in 1,243 real-world PCI patients from the ran-
domised TWENTE trial7,8, treated with second-generation drug-
eluting stents (DES), we assessed the relation between SYNTAX 
score and the occurrence of PMI, as defined by the extended his-
torical WHO definition as well as the recently updated third uni-
versal definition of MI.
Methods
STUDY DESIGN AND PATIENT POPULATION
The randomised TWENTE trial (ClinicalTrials.gov NCT01066650) 
has previously been described and reported7,8. In brief, TWENTE 
was an investigator-initiated, patient-blinded, randomised, com-
parative DES trial with limited exclusion criteria in 1,391 “real-
world” PCI patients with a majority of complex lesions and 
off-label indications for DES. The study was performed between 
June 2008 and August 2010 at Thoraxcentrum Twente, Enschede, 
The Netherlands. Patients capable of providing informed con-
sent with an indication for PCI with DES were randomised for 
treatment with Resolute™ (Medtronic, Santa Rosa, CA, USA) or 
XIENCE V® stents (Abbott Vascular, Santa Clara, CA, USA) in 
a 1:1 ratio. There were no angiographic exclusion criteria such as 
a mandatory lesion length, reference vessel size, and number of 
target lesions or vessels. The main exclusion criterion was a recent 
ST-elevation myocardial infarction (STEMI). More than 81% of 
the eligible patients were enrolled in this trial9.
In all trial participants, except for 148 patients with a history of 
CABG, SYNTAX score was prospectively assessed by analysts of 
the angiographic core laboratory at the Thoraxcentrum, Twente. 
The study was approved by the institutional ethics committee and 
complied with the Declaration of Helsinki. All patients provided 
written informed consent.
DEFINITION AND ASSESSMENT OF PMI
PMI was defined by the extended historical WHO definition 
(WHO PMI; total CK >2x normal with elevated CK-MB or, in 
the case of ongoing MI, CK >2x normal and ≥50% above the 
previous level if the baseline values are elevated, in addition to 
symptoms) and the third universal definition of MI (troponin >5x 
normal or, in the case of ongoing MI, a rise of troponin values 
>20% if the baseline values are elevated, in addition to symptoms, 
ECG changes, angiographic findings or new regional wall motion 
abnormalities)10,11.
In all patients, cardiac biomarkers and electrocardiograms were 
systematically assessed before and after index PCI or staged pro-
cedure in order to identify PMI. Cardiac biomarker measurements 
were scheduled before PCI and six to 18 hours after PCI, with 
subsequent serial measurements for relevant biomarker increases 
or complaints, until peak increase was established. Adjudication of 
WHO PMI was performed by an external clinical events commit-
tee (Cardialysis, Rotterdam, The Netherlands), and adjudication of 
PMI according to the universal definition of MI was performed by 
three experienced cardiologists/research physicians.
STATISTICAL ANALYSIS
Categorical variables were assessed with the use of the χ2 or Fisher’s 
exact test, as appropriate, whereas continuous variables were assessed 
with the Wilcoxon rank-sum test or Student’s t-test, as appropriate. 
Means are given with standard deviation (SD) and medians with an 
interquartile range (IQR). Univariate and multivariate logistic regres-
sion analyses were performed to assess the relationship between the 
SYNTAX score and PMI. We constructed three models: Model 1 
including clinical variables with a univariate association with PMI 
p<0.10; Model 2 being the full model with variables with a univari-
ate association with PMI p<0.10, in addition to other clinical vari-
ables used in similar research which evaluated the SYNTAX score 
and its relation to clinical outcome (i.e., presentation with acute cor-
onary syndrome, age, sex, stent type, history of MI, history of PCI, 
and chronic renal failure)12. In Model 3, only the SYNTAX score and 
the variable total stent length were entered into the model. Variables 
were simultaneously put into a multivariate model using the forced 
enter method, without exit criteria. Variables which are included in 
the SYNTAX score (i.e., vessel diameter, lesion length) were not 
included in the model to avoid collinearity. The variable left ventric-
ular ejection fraction (LVEF) <30% was not included in this model, 
as data on LVEF were not available for all patients. In order to com-
pare SYNTAX score versus the AHA/ACC lesion classification and 
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Value of SYNTAX score for PMI
their relation to PMI, we compared the -2 log-likelihood of the full 
multivariate model with SYNTAX score in it with the -2 log-likeli-
hood of the same model but with the SYNTAX score replaced by the 
AHA/ACC lesion classification. A higher -2 log-likelihood suggests 
a better model.
Unless otherwise specified, p-values and confidence intervals 
(CIs) were two-sided. A p-value <0.05 was considered significant. 
All statistical analyses were performed with SPSS Version 15.0 
(SPSS Inc., Chicago, IL, USA).
Results
SYNTAX SCORE AND BASELINE CHARACTERISTICS
The SYNTAX score was assessed in 1,243 of the 1,391 patients 
(89.4%) of the TWENTE trial who had not undergone previous 
CABG. The mean SYNTAX score was 12.45±8.36, and the median 
SYNTAX score was 11.00 (IQR 6.00-24.00). Based on tertiles of 
the SYNTAX score, the SYNTAX score was ≤7.0 in 430 patients, 
>7.0 and <15.0 in 390 patients, and ≥15 in 423 patients.
Baseline characteristics and angiographic and procedural char-
acteristics are described in Table 1 and Table 2. Patients with 
the highest SYNTAX score (≥15) were older (p<0.001) and were 
more likely to have an LVEF <30% (p=0.008) and a previous 
myocardial infarction (p<0.001). Post-dilation with balloon pres-
sures >18 atm and use of glycoprotein IIb/IIIa antagonists were 
more frequent in patients with a higher SYNTAX score (p<0.001). 
Medication at discharge did not differ between groups (Table 3).
INCIDENCE OF PMI
The incidence of PMI according to the extended historical 
WHO definition and universal definition, stratified for SYNTAX 
Table 1. Baseline characteristics of patients.
Study population 
(n=1,243)
SYNTAX score ≤7.0 
(n=430)
SYNTAX score >7.0 and 
<15 (n=390)
SYNTAX score ≥15 
(n=423)
p-value across 
groups
Age (yrs) 63.8 (10.6) 62.2 (10.8) 64.1 (10.6) 65.2 (10.1) <0.01
Men 890 (71.6) 303 (70.5) 277 (71.0) 310 (73.3) 0.63
Body mass index (kg/m²)* 27.7 (4.0) 27.9 (4.2) 27.6 (3.9) 27.7 (3.9) 0.56
Diabetes mellitus 262 (21.1) 89 (20.7) 84 (21.5) 89 (21.0) 0.96
Diabetes mellitus receiving insulin 90 (7.2) 34 (7.9) 25 (6.4) 31 (7.3) 0.71
Chronic renal failure¶ 32 (2.6) 9 (2.1) 7 (1.8) 16 (3.8) 0.15
Arterial hypertension 690 (55.5) 239 (55.6) 208 (5.3) 243 (57.4) 0.50
Hypercholesterolaemia 700 (57.8) 248 (58.8) 216 (56.8) 236 (57.6) 0.86
Current smoker 324 (26.1) 119 (27.7) 98 (25.1) 107 (25.3) 0.64
Family history of CAD 651 (52.4) 226 (52.6) 204 (52.3) 221 (52.2) 1.00
Myocardial infarction (any) 392 (31.5) 107 (24.9) 123 (31.5) 162 (38.3) <0.01
Previous PCI 234 (18.8) 90 (20.9) 77 (19.7) 67 (15.8) 0.14
Clinical indication 0.24
Stable angina pectoris 591 (47.5) 203 (47.2) 182 (46.7) 206 (48.7)
Unstable angina 285 (22.9) 95 (22.1) 104 926.7) 86 (20.3)
Non-ST-elevation MI 367 (29.5) 132 (30.7) 104 (26.7) 131 (31.0)
Clinical indication: acute coronary syndrome 652 (52.5) 227 (52.8) 208 (53.3) 217 (51.3) 0.83
Left ventricular ejection fraction <30% ‡ 25/919 (2.6) 5/313 (1.6) 4/298 (1.3) 16/313 (4.9) <0.01
Multivessel treatment 293 (23.6) 25 (5.8) 99 (25.4) 169 (40.0) <0.01
Total no. of lesions treated per patient <0.01
One lesion treated 762 (61.3) 370 (86.0) 221 (56.7) 171 (40.4)
Two lesions treated 357 (28.7) 54 (12.6) 142 (36.4) 161 (38.1)
Three or more lesions treated 124 (10.0) 6 (1.4) 27 (6.9) 91 (21.5)
Only de novo coronary lesions treated § 60 (4.8) 16 (3.7) 27 (6.9) 17 (4.0) 0.07
At least one CTO treated 83 (6.7) 8 (1.9) 17 (4.4) 58 (13.7) <0.01
At least one bifurcation treated 337 (27.1) 39 (9.1) 107 (27.4) 191 (45.2) <0.01
At least one bifurcation with side branch treated 199 (16.0) 17 (4.0) 69 (17.7) 113 (26.7) <0.01
At least one in-stent restenosis treated 60 (4.8) 16 (3.7) 27 (6.9) 17 (4.0) 0.07
At least one small vessel (RVD <2.75 mm) 793 (63.8) 231 (53.7) 244 (62.6) 318 (75.2) <0.01
At least one long lesion (length >27 mm) treated 259 (20.8) 33 (7.7) 87 (22.3) 139 (32.9) <0.01
Glycoprotein IIb/IIIa antagonist use 176 (14.2) 37 (8.6) 46 (11.8) 93 (22.0) <0.01
Data are number (%) or mean (SD). *assessed in 1,064 patients. ¶ chronic renal failure defined by serum creatinine level ≥130 µmol/L. ‡ left ventricular ejection fraction assessed with 
ultrasound, MRI or LV angiography. § including chronic total occlusion, but not grafts and in-stent restenosis. BMI: body mass index; CABG: coronary artery bypass grafting; CAD: coronary 
artery disease; CTO: chronic total occlusion; MI: myocardial infarction; PCI: percutaneous coronary intervention; RVD: reference vessel diameter
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score, is shown in Table 4. MI according to the extended his-
torical WHO definition occurred more frequently in patients 
of the highest SYNTAX score tertile (7.3% vs. 3.1% vs. 1.6%, 
p<0.001) as compared to the mid and lowest SYNTAX score ter-
tiles. In addition, PMI according to the third universal definition 
occurred more frequently in patients of the highest SYNTAX 
score tertile (9.9% vs. 7.7% vs. 3.7%, p=0.002). The difference 
in definitions of PMI impacts on the diagnosis of PMI. This is 
shown in Figure 1.
CAUSES OF PMI
The causes of PMI are shown in Table 5. According to the 
extended historical WHO definition, the cause of PMI was a ves-
sel dissection in 20%, side branch occlusion in 28%, no reflow 
in 16%, and embolisation or stent thrombosis in 6%. In 42%, no 
angiographic reason was found for the occurrence of WHO PMI. 
For PMI according to the third universal definition, the cause 
of PMI was a vessel dissection in 19%, side branch occlusion 
in 52%, no reflow in 24% and embolisation or stent thrombosis 
Table 2. Angiographic and procedural characteristics.
Study population 
(n=1,243)
SYNTAX score ≤7.0 
(n=430)
SYNTAX score >7.0 and 
<15 (n=390)
SYNTAX score ≥15 
(n=423)
p-value
Target lesion coronary artery
Left anterior descending 695 (55.9) 143 (33.3) 216 (55.4) 336 (79.4) <0.01
Left circumflex 391 (31.5) 133 (30.9) 119 (30.5) 139 (32.9) 0.74
Right coronary artery 453 (36.4) 181 (42.1) 151 (38.7) 121 (28.6) <0.01
Left main 23 (1.9) 0 9 (2.3) 14 (3.3) <0.01
Multivessel treatment 293 (23.6) 25 (5.8) 99 (25.4) 169 (40.0) <0.01
Total lesions treated per patient <0.01
One lesion treated 762 (61.3) 370 (86.0) 221 (56.7) 171 (40.4)
Two lesions treated 357 (28.7) 54 (12.6) 142 (36.4) 161 (38.1)
Three or more lesions treated 124 (10.0) 6 (1.4) 27 (6.9) 91 (21.5)
No. of stents placed 2.02 (1.18) 1.38 (0.69) 2.00 (0.97) 2.68 (1.38) <0.01
ACC-AHA lesion class B2 or C lesion treated 702 (56.5) 126 (29.3) 241 (61.8) 335 (79.2) <0.01
At least one ostial lesion treated 113 (9.1) 28 (6.5) 51 (13.1) 34 (8.0) <0.01
Preprocedural TIMI flow (grade 0-1) 99 (8.0) 24 (5.6) 35 (9.0) 40 (9.5) 0.08
At least one lesion directly stented 414 (33.3) 196 (45.6) 124 (31.8) 94 (22.2) <0.01
At least one stent post-dilated >18 atm 954 (76.7) 301 (70.0) 293 (75.1) 630 (85.1) <0.01
Data are number (%) or mean (SD). ACC: American College of Cardiology; ACE: angiotensin-converting enzyme; AHA: American Heart Association; ARB: angiotensin receptor 
blockers; CTO: chronic total occlusion; DM: diabetes mellitus; RVD: reference vessel diameter; TIMI: Thrombolysis In Myocardial Infarction
Table 3. Medication at discharge.
Study population 
(n=1,243)
SYNTAX score ≤7.0 
(n=430)
SYNTAX score >7.0 and 
<15 (n=390)
SYNTAX score ≥15 
(n=423)
p-value
Antiplatelet therapy Acetylsalicylic acid 1,233 (99.2) 426 (99.1) 387 (99.2) 420 (99.3) 0.93
Clopidogrel 1,243 (100) 430 (100) 390 (100) 423 (100) 1.00
Other medication Statin 1,061 (85.4) 369 (85.8) 339 (86.9) 353 (83.5) 0.36
Beta-blocker 1,026 (82.5) 353 (82.1) 335 (85.9) 338 (79.9) 0.08
ACE/ARB 581 (46.7) 203 (47.2) 165 (42.3) 213 (50.4) 0.07
Data are number (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers
All patients
n=1,243
Third universal
definition
WHO
definition
18 (1.4%) 32 (2.6%) 56 (4.5%)
Figure 1. Venn diagram illustrating the overlap and differences of 
the definitions of PMI according to the WHO and third universal 
definition.
in 6%. In 18%, no angiographic reason was found for the occur-
rence of PMI according to the updated third universal definition. 
As shown, certain causes were not statistically more prevalent in 
higher SYNTAX scores.
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Value of SYNTAX score for PMI
MULTIVARIATE ANALYSIS
Table 6 shows the complete results of the multivariate analysis. 
After multivariate analysis, adjusting for covariates, SYNTAX 
score was a significant independent predictor of PMI according to 
both definitions. Patients with the highest tertile of the SYNTAX 
score, compared to the lowest tertile, had an almost five times 
higher risk of PMI according to the historical WHO definition 
(adjusted odds ratio [OR] 4.95, 95% confidence interval [CI]: 
2.13-11.52) and an almost three times higher risk according to the 
updated PMI definition (adjusted OR 2.84, 95% CI: 1.55-5.19) 
(Figure 2). On a continuous scale, SYNTAX score was also a sig-
nificant independent predictor of PMI according to the extended 
Table 4. The incidence of PMI according to the extended historical WHO definition and third universal definition, stratified for SYNTAX score.
Study population 
(n=1,243)
SYNTAX score 
≤7.0 (n=430)
SYNTAX score >7.0 
and <15 (n=390)
SYNTAX score ≥15 
(n=423)
p-value
PMI according to historical WHO definition 50 (4.0) 7 (1.6) 12 (3.1) 31 (7.3) <0.001
PMI according to third universal definition 88 (7.1) 16 (3.7) 30 (7.7) 42 (9.9) 0.002
Data are number (%).
Table 5. Causes of periprocedural myocardial infarction.
SYNTAX score ≤7.0 SYNTAX score >7.0 and <15 SYNTAX score ≥15 p-value
Cause of WHO PMI
Vessel dissection 1 (14.3) 3 (25) 6 (19.4) 0.88
Side branch occlusion 2 (28.6) 4 (28.6) 8 (57.1) 0.90
No reflow 0 (0) 1 (8.3) 7 (22.6) 0.33
Embolisation or stent thrombosis 0 (0) 1 (8.3) 2 (6.5) 1.00
No evident cause 4 (66) 6 (50) 11 (35) 0.40
Cause of third universal definition PMI
Vessel dissection 2 (12.5) 5 (16.7) 10 (23.8) 0.63
Side branch occlusion 8 (50.0) 15 (50.0) 23 (56.1) 0.85
No reflow 4 (25.0) 6 (20.0) 11 (26.2) 0.80
Embolisation or stent thrombosis 1 (6.3) 1 (3.3) 3 (7.1) 0.85
Data are number (% of all periprocedural myocardial infarctions).
0 1 2 3 4 5 6 7 8 9 10 11 12
T3 (S×S ≥15)
T2 (S×S >7.0-<15)
T1 (S×S ≤7.0, reference)
OR 4.95 (95% CI: 2.13-11.52)
p<0.001
OR 1.93 (95% CI: 0.75-4.98)
p=0.17
0 1 2 3 4 5 6 7 8 9 10 11 12
T3 (S×S ≥15)
T2 (S×S >7.0-<15)
T1 (S×S ≤7.0, reference)
OR 2.84 (95% CI: 1.55-5.19)
p=0.001
OR 2.14 (95% CI: 1.15-4.01)
p=0.017
A
B
Figure 2. Multivariate adjusted odds ratios (OR) of SYNTAX score tertiles for periprocedural myocardial infarction according to the WHO 
definition (A), and third universal defintion of MI (B).
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Table 6. Univariate and multivariate analysis with both definitions of PMI. 
Clinical variable Odds ratio (95% CI)WHO MI
Odds ratio (95% CI)
Third definition MI
SYNTAX score
Low SYNTAX tertile (reference) Reference Reference
Mid SYNTAX tertile 1.92 (0.75-4.92) 0.18 2.16 (1.16-4.02) 0.02
High SYNTAX tertile 4.78 (2.08-10.98) <0.01 2.85 (1.58-5.16) <0.01
Age (yrs ) 1.01 (0.98-1.04) 0.59 1.00 (0.98-1.02) 1.00
Female 1.31 (0.72-2.39) 0.37 0.94 (0.58-1.53) 0.81
Body mass index (kg/m²) * 1.03 (0.96-1.11) 0.40 1.05 (0.99-1.11) 0.11
Diabetes mellitus 1.33 (0.70-2.54) 0.39 0.89 (0.51-1.54) 0.68
Diabetes mellitus receiving insulin 2.18 (0.96-4.99) 0.07 0.93 (0.40-2.20) 0.87
Chronic renal failure ¶ 0.77 (0.10-5.72) 0.77 0.87 (0.21-3.71) 0.85
Arterial hypertension 1.11 (0.63-1.97) 0.72 0.83 (0.54-1.28) 0.39
Hypercholesterolaemia 1.19 (0.65-2.16) 0.58 1.04 (0.66-1.63) 0.88
Current smoker 0.53 (0.25-1.14) 0.11 0.77 (0.45-1.30) 0.32
Family history of CAD 0.77 (0.43-1.35) 0.36 1.00 (0.65-1.54) 0.98
Peripheral artery disease 1.09 (0.39-3.11) 0.87 1.34 (0.62-2.87) 0.45
Myocardial infarction (any) 1.23 (0.68-2.22) 0.49 1.48 (0.95-2.30) 0.09
Previous PCI 1.23 (0.62-2.43) 0.56 1.12 (0.65-1.92) 0.69
Clinical indication
Stable angina pectoris Reference Reference
Unstable angina 0.71 (0.33-1.53) 0.38 1.07 (0.62-1.84) 0.82
Non-ST-elevation MI 0.93 (0.48-1.77) 0.82 1.02 (0.61-1.70) 0.93
Clinical indication: acute coronary syndrome 0.83 (0.47-1.46) 0.52 1.04 (0.68-1.61) 0.85
Left ventricular ejection fraction <30% ‡ 0.89 (0.12-6.76) 0.91 0.55 (0.07-4.11) 0.56
Multivessel treatment 2.91 (1.63-5.16) <0.01 1.96 (1.24-3.09) <0.01
Total no. of lesions treated per patient
One lesion treated Reference Reference
Two lesions treated 2.77 (1.42-5.41) <0.01 1.75 (1.06-2.87) 0.03
Three of more lesions treated 5.93 (2.82-12.50) <0.01 3.66 (2.05-6.54) <0.01
Only de novo coronary lesions treated § 0.82 (0.19-3.43) 0.78 1.21 (0.47-3.09) 0.70
At least one CTO treated 1.59 (0.61-4.12) 0.34 1.02 (0.43-2.42) 0.96
At least one bifurcation treated 2.39 (1.35-4.22) <0.01 2.18 (1.40-3.39) <0.01
At least one bifurcation with side branch treated 1.51 (0.76-3.00) 0.24 1.97 (1.19-3.25) <0.01
At least one in-stent restenosis treated 0.82 (0.19-3.43) 0.78 1.21 (0.47-3.09) 0.70
At least one small vessel (RVD <2.75 mm) 2.06 (1.05-4.07) 0.04 1.05 (0.67-1.65) 0.84
At least one long lesion (length >27 mm) treated 2.91 (1.63-5.19) <0.01 2.60 (1.65-4.10) <0.01
Glycoprotein IIb/IIIa antagonist use 4.43 (2.46-8.00) <0.01 5.60 (3.54-8.85) <0.01
Stent type (XIENCE vs. Resolute [ref]) 0.87 (0.49-1.53) 0.62 1.45 (0.94-2.25 0.10
Multivariate Model 1. Model 1 includes the SYNTAX score as well as clinical variables with a univariate association with PMI p<0.10.
Clinical variable Adjusted odds ratio  (95% CI) WHO MI
Adjusted odds ratio  
(95% CI)
Third definition MI
SYNTAX score
Low SYNTAX tertile (reference) Reference Reference
Mid SYNTAX tertile 1.95 (0.76-5.01) 0.17 2.11 (1.13-3.94) 0.02
High SYNTAX tertile 4.80 (2.08-11.09) <0.01 2.74 (1.51-4.97) <0.01
Diabetes mellitus receiving insulin 2.23 (0.96-5.18) 0.06 0.94 (0.39-2.22) 0.88
Myocardial infarction (any) 1.04 (0.57-1.90) 0.89 1.35 (0.86-2.11) 0.18
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Value of SYNTAX score for PMI
Table 6. Univariate and multivariate analysis with both definitions of PMI (cont’d).
Multivariate Model 2. Model 2 includes variables with a univariate association with PMI p<0.10 as well as the covariates presentation 
with acute coronary syndrome, age, sex, stent type, history of MI, history of PCI, and chronic renal failure.
Clinical variable
Adjusted odds ratio  
(95% CI) WHO MI
Adjusted odds ratio  
(95% CI)
Third definition MI
SYNTAX score
Low SYNTAX tertile (reference) Reference
Mid SYNTAX tertile 1.93 (0.75-4.98) 0.17 2.11 (1.13-3.94) 0.02
High SYNTAX tertile 4.95 (2.13-11.52) <0.01 2.84 (1.55-5.19) <0.01
Diabetes mellitus receiving insulin 1.30 (0.67-2.53) 0.43 1.06 (0.44-2.55) 0.89
Myocardial infarction (any) 1.06 (0.56-2.01) 0.86 1.31 (0.81-2.13) 0.28
Age (yrs) 1.00 (0.97-1.03) 0.86 0.99 (0.97-1.02) 0.54
Female 1.37 (0.74-2.57) 0.32 1.02 (0.62-1.68) 0.95
Stent type (XIENCE vs. Resolute [ref]) 0.86 (0.49-1.54) 0.62 1.44 (0.92-2.24) 0.11
Myocardial infarction (any) 1.06 (0.56-2.02) 0.86 1.31 (0.81-2.13) 0.28
Previous PCI 1.34 (0.65-2.76) 0.43 1.06 (0.60-1.89) 0.84
Chronic renal failure 0.60 (0.08-4.64) 0.63 0.82 (0.19-3.58) 0.79
Multivariate Model 3. In Model 3, only the SYNTAX score and the variable stent length were entered in a multivariate model.
Clinical variable
Adjusted odds ratio  
(95% CI) WHO MI
Adjusted odds ratio  
(95% CI)
Third definition MI
SYNTAX score
Low SYNTAX tertile (reference) Reference Reference
Mid SYNTAX tertile 1.42 (0.54-3.72) 0.48 1.43 (0.75-2.74) 0.27
High SYNTAX tertile 2.50 (0.98-6.37) 0.054 1.22 (0.61-2.42) 0.58
Total stent length implanted 1.02 (1.01-1.03) <0.01 1.02 (1.02-1.03) <0.01
historical WHO definition (adjusted OR 1.07, 95% CI: 1.04-1.10, 
p<0.001) and the third universal definition (adjusted OR 1.04, 
95% CI: 1.01-1.06, p=0.002). When total stent length implanted 
was entered into the multivariate model (Model 3), there was 
a trend that patients with the highest tertile of the SYNTAX score, 
compared to the lowest tertile, had a higher risk of PMI accord-
ing to the WHO definition (adjusted OR 2.51, 95% CI: 0.98-6.39, 
p=0.054), but not according to the third definition of MI. Total 
stent length implanted was also a significant correlate for both def-
initions of PMI.
The full multivariate model with the SYNTAX score in it 
had a better correlation with PMI than the same model with the 
SYNTAX score being replaced by the AHA/ACC lesion classifi-
cation (-2 log-likelihood of 407.6 versus 396.8). This suggests that 
the SYNTAX score is a better correlate of PMI.
Discussion
MAIN FINDINGS
The SYNTAX score is an independent correlate of PMI according 
to both the extended historical WHO definition10 and the recently 
updated universal definition of MI11. According to the historical 
WHO definition, patients with the highest tertile of the SYNTAX 
score, compared to the lowest tertile, had an almost five times 
higher risk of PMI (adjusted OR 4.95 [2.13-11.52]) and, accord-
ing to the updated PMI definition, an almost three times higher 
risk (adjusted OR 2.84 [1.55-5.19]). Our data demonstrate that 
PCI patients with complex coronary artery disease have a higher 
PMI risk, and that the SYNTAX score correlated better to PMI 
than the AHA/ACC lesion classification. The present substudy of 
the TWENTE trial shows that the SYNTAX score independently 
predicts PMI in a large clinical trial with randomised data, exter-
nal adjudication and core laboratory analysed data. These results 
are consistent with the findings from van Gaal et al who first 
described this relation in a registry13.
SYNTAX SCORE AND PMI
PMI is the most common adverse event after PCI and occurs in 
5% to 30% of procedures, depending on patient population, local 
practice of post-procedural assessment of cardiac markers, and the 
diagnostic criteria applied14-17. Some studies have shown a relation 
between PMI and adverse outcome4-6.
In previous studies, the SYNTAX score has been shown to be 
associated with adverse long-term clinical outcome6,12,18; how-
ever, there are limited data on the value of the SYNTAX score 
on periprocedural complications in a broad population of patients 
undergoing PCI.
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Van Gaal et al previously assessed 100 patients with stable 
coronary artery disease and suggested, based on their findings 
in this relatively small population, that the SYNTAX score was 
associated with periprocedural necrosis13. Farooq et al recently 
reported, in a post hoc analysis of the SYNTAX trial, that a higher 
SYNTAX score was associated with an increased risk of PMI in 
827 patients undergoing PCI with first-generation DES (TAXUS; 
Boston Scientific, Marlborough, MA, USA) for severe (three-ves-
sel or left main) coronary artery disease6.
Our study population differs significantly from both of the afore-
mentioned studies, as 10% of our patients had a history of previous 
CABG, 58% presented with acute coronary syndromes, and only 
24% underwent multivessel PCI19. The findings of our present study 
extend current knowledge by showing that, even in a broad popu-
lation of contemporary PCI patients treated with second-generation 
DES, a higher SYNTAX score is related to an increased PMI risk.
Risk factors for PMI are associated with the burden of athero-
sclerotic disease (i.e., multivessel disease, calcification) and lesion 
complexity (i.e., thrombus formation, lesion eccentricity)20,21. 
These risk factors are also included in the SYNTAX score, which 
is a tool to assess the severity and complexity of coronary ath-
erosclerotic disease burden. A higher SYNTAX score reflects 
more complex coronary artery disease, with longer lesions and/or 
smaller arteries which might result in higher risk for vessel dissec-
tion, side branch occlusion, no reflow or vessel occlusion causing 
a PMI. While numerically these causes occurred frequently in the 
highest SYNTAX tertile, no statistical difference was shown in 
the causes for PMI throughout the SYNTAX tertiles, which might 
have been due to the low number of events.
When the variable total stent length implanted was entered into 
the multivariate model, the value of the SYNTAX score as cor-
relate for PMI was diminished, while total stent length implanted 
was significantly correlated with PMI. Total stent length is known 
to be related to lesion length, and its relation with PMI may thus 
be explained by the same mechanisms as previously mentioned. 
As the parameter lesion length is included in the SYNTAX score, 
collinearity may also be the reason that the value of the SYNTAX 
score was diminished when the variable total stent length was 
entered into a multivariate model.
DEFINITION OF PMI
Various clinical trials have applied different definitions of MI and 
PMI. In an attempt to standardise definitions, a joint European 
Society of Cardiology, American College of Cardiology, American 
Heart Association, and World Health Organization Task Force for 
the development of a Universal Definition of Myocardial Infarction 
has been established. With the development of even more sensitive 
assays for markers of myocardial necrosis and new insights from 
recent studies, the universal definition of MI has recently been 
updated11 to make the definition more specific. In contrast to the 
second universal definition of MI, higher troponin values along 
with supplemental clinical information are now required in order 
to diagnose a PMI.
In the present study, we used the extended historical WHO def-
inition as well as the third universal definition of MI to assess 
a potential relation between SYNTAX score and PMI. This rela-
tion was shown for both definitions, indicating that the relation 
between SYNTAX score and PMI was not related to the use of one 
particular definition only. Nevertheless, this relation was stronger 
for the WHO definition of MI, which uses a higher threshold for 
identifying PMI.
While several previous studies have shown a relation between 
PMI and short-term and long-term clinical outcome6,21, there is 
still an ongoing discussion on this issue as other studies showed 
no such relation4,22,23. PMI with limited marker release may have 
no impact on the clinical course, which recently even triggered 
the suggestion of a new “clinically relevant” definition of PMI24.
IMPLICATIONS
Preprocedural assessment of the SYNTAX score could help to 
identify patients at an increased risk of PMI, which might then 
trigger preventive measures. In patients with a particularly high 
risk of PMI, pretreatment with drugs that have anti-inflammatory 
and/or antithrombotic properties might be considered, such as 
high-dose or early initiation of statin therapy25,26, administration of 
a glycoprotein IIb/IIIa antagonist27,28, and perhaps even the initia-
tion of pharmacologic treatment for glycaemic control in patients 
with previously unrecognised diabetes mellitus29.
Limitations
This substudy of the TWENTE trial is limited by its post hoc 
nature, and the findings should be considered as hypothesis-gen-
erating only. Patients undergoing primary PCI were not included 
in the TWENTE trial. No data on residual SYNTAX score were 
available in this study.
Conclusion
In a broad population of patients treated with second-generation 
DES, the SYNTAX score was able to stratify the risk of periproce-
dural myocardial infarction according to both the WHO definition 
and the third universal definition of myocardial infarction.
Impact on daily practice
Several studies have shown a relation between periproce-
dural myocardial infarction and an unfavourable outcome. 
The SYNTAX score may be a useful tool for risk stratifica-
tion for a periprocedural myocardial infarction, and preproc-
edural assessment of the SYNTAX score could help to identify 
patients at an increased risk of PMI, which might trigger pre-
ventive measures.
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